Suppr超能文献

雄激素剥夺疗法与前列腺癌患者中风风险。

Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer.

机构信息

Centre for Clinical Epidemiology and Community Studies, Sir Mortimer B. Davis Jewish General Hospital, Montreal, Quebec, Canada.

出版信息

Eur Urol. 2011 Dec;60(6):1244-50. doi: 10.1016/j.eururo.2011.08.041. Epub 2011 Aug 27.

Abstract

BACKGROUND

Some evidence indicates that androgen-deprivation therapy (ADT) increases the risk of diabetes and cardiovascular disease. To date, few studies have investigated whether this therapy also increases the risk of cerebrovascular events.

OBJECTIVE

To determine whether different types of ADT increase the risk of stroke/transient ischaemic attacks (TIAs) in patients with prostate cancer.

DESIGN, SETTING, AND PARTICIPANTS: We conducted a population-based cohort study using a nested case-control analysis within the United Kingdom's General Practice Research Database population. The cohort included all patients at least 40 yr of age newly diagnosed with prostate cancer between January 1, 1988, and December 31, 2008, and followed until December 31, 2009. Cases consisted of those who experienced a first-ever stroke/TIA during follow-up. Up to 10 controls were matched to each case on age, year of cohort entry, and duration of follow-up.

MEASUREMENTS

Adjusted rate ratios (RRs) of stroke/TIA associated with the use of different ADTs (gonadotropin-releasing hormone [GnRH] agonists, oral antiandrogens, combined androgen blockade, bilateral orchiectomy, and others) were estimated using conditional logistic regression.

RESULTS AND LIMITATIONS

The cohort included 22 310 patients with prostate cancer, followed for a mean of 3.9 yr, where 938 patients experienced a first-ever stroke/TIA (rate: 10.7 per 1000/yr). Compared with nonusers of ADT, current users of GnRH agonists (adjusted RR: 1.18; 95% confidence interval [CI], 1.00-1.39), oral antiandrogens (adjusted RR: 1.47; 95% CI, 1.08-2.01), and those who underwent bilateral orchiectomy (adjusted RR: 1.77; 95% CI, 1.25-2.39) were at an increased risk of stroke/TIA. No statistically significant increased risks were observed for patients on combined androgen blockade and other ADTs, but the small numbers do not rule out a possible association.

CONCLUSIONS

The results of this large population-based study provide additional evidence that different forms of ADT may increase the risk of stroke/TIA.

摘要

背景

有证据表明,去势治疗(ADT)会增加糖尿病和心血管疾病的风险。迄今为止,很少有研究调查这种治疗是否也会增加脑血管事件的风险。

目的

确定不同类型的 ADT 是否会增加前列腺癌患者发生中风/短暂性脑缺血发作(TIA)的风险。

设计、设置和参与者:我们进行了一项基于人群的队列研究,使用嵌套病例对照分析方法,在英国全科医生研究数据库人群中进行。该队列包括所有年龄至少为 40 岁、1988 年 1 月 1 日至 2008 年 12 月 31 日期间首次确诊为前列腺癌的患者,并随访至 2009 年 12 月 31 日。病例由随访期间首次发生中风/TIA 的患者组成。每个病例最多匹配 10 个对照,匹配因素包括年龄、队列进入年份和随访时间。

测量

使用条件逻辑回归估计不同 ADT(促性腺激素释放激素[GnRH]激动剂、口服抗雄激素、联合雄激素阻断、双侧睾丸切除术和其他)使用与中风/TIA 相关的调整后率比(RR)。

结果和局限性

该队列包括 22310 名前列腺癌患者,平均随访 3.9 年,其中 938 名患者发生首次中风/TIA(发生率:10.7/1000 人/年)。与未使用 ADT 的患者相比,目前使用 GnRH 激动剂(调整后 RR:1.18;95%置信区间[CI],1.00-1.39)、口服抗雄激素(调整后 RR:1.47;95%CI,1.08-2.01)和接受双侧睾丸切除术(调整后 RR:1.77;95%CI,1.25-2.39)的患者中风/TIA 风险增加。未观察到联合雄激素阻断和其他 ADT 患者的风险显著增加,但数量较少不排除可能存在关联。

结论

这项大型基于人群的研究结果提供了额外的证据,表明不同形式的 ADT 可能会增加中风/TIA 的风险。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验